



Steve Arlington,

Partner, Global Pharmaceuticals & Life Sciences Advisory Leader

Steve has considerable experience of working in and consulting to the pharmaceutical industry, strategic studies, new product and business development and manufacturing across the healthcare industry.

Steve has over seventeen years experience within the industry in pharmaceutical research and development both as a team leader and group research manager. He has worked in diagnostics and medical devices, and has been involved in the development and launch of world class drugs and diagnostic tests. He has also set up a patient compliance business.

Within PwC, Steve leads the Global Pharmaceuticals and Life Sciences Advisory team where he works extensively with company boards and senior management, in the areas of strategy, marketing, R&D and regulatory affairs. He has over fifteen years of experience in leading complex, multi-national programmes within the healthcare environment. He leads the recently released thought leadership reports Pharma 2020 focussing on strategy, R+D and marketing and sales. Previously, he authored the highly acclaimed thought leadership points of view: “Pharma 2005: An Industrial Revolution in R&D”, “Pharma 2005: The Race to e-R&D”, “Pharma 2005: Marketing to the Individual” and “Pharma 2010: The Threshold of Innovation”.

In 2005 Steve set up a new venture medAmigo. This company was set up to improve patient compliance and persistence in the field of marketed Rx drugs. Funding was secured from 3i ventures (\$6m). Previously, he led the IBM Life Sciences and Pharmaceutical Global Team. Steve is a visiting professor at University College London, Department of Biochemical Engineering and he is a member of the Royal Society of Medicine, the Drug Information Association (DIA), and teaches at FDA, SFDA and EMA Drug Development Programmes.